ascopubs.org

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma Fifty-eight participants were ...
Nasdaq

Oxford Immunotec Announces the Approval of the T-Cell Select™ Reagent Kit, Used to Automate the T-SPOT®.TB Test Workflow, for IVD Use in South Korea

OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announced ...
Healio

Patient Selection: The Key First Step to Successful CAR T-cell Therapy

Please provide your email address to receive an email when new articles are posted on . In the In Practice column, Cell Therapy Next will work with members of the Peer Perspective Board to break down ...
The American Journal of Managed Care

Patient Selection of CAR T-Cell Therapy in R/R NHL

Jeff Sharman, MD, provides insight on patient eligibility for CAR T therapy, managing barriers to access, and steps for monitoring patients with R/R NHL post-treatment. Transcript Jeff Sharman, MD: ...
WBJournal

Oxford Immunotec receives approval to bring reagent kit to South Korea

South Korea’s Ministry of Food and Drug Safety has given the greenlight to Oxford Immunotec’s T-Cell Select reagent kit, the Marlborough diagnostics company announced on Thursday. The reagent kit is ...
Business Insider

Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110TM, a KIR-CAR T-cell Immunotherapy Candidate

Company advances towards in-human clinical trials for SynKIR TM platform targeting Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, and Mesothelioma PHILADELPHIA, Aug. 19, 2022 ...
KXAN

Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110TM, a KIR-CAR T-cell Immunotherapy Candidate

Company advances towards in-human clinical trials for SynKIR TM platform targeting Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, and Mesothelioma "Initiation of the STAR-101 ...